Drug Discovery World

APRIL 12, 2024

The top stories: Genetically engineered dendritic cells enhance lung cancer therapy A study by researchers at the UCLA Health Jonsson Comprehensive Cancer Center in the US suggests that injecting engineered dendritic cells directly into cancerous lung tumours can help promote a stronger immune response.

Immune Response 130

Immune Response Engineering Drugs Therapies 130

Drug Discovery World

MAY 23, 2024

The researchers will use a genetically engineered herpes simplex virus type 1 to eliminate cancer cells. The virus is engineered to enter the cancer cells and replicate rapidly, which breaks the cells open and exposes them to the immune system, effectively destroying them. million of funding for this research project.

Virus 148

Virus Immune Response Vaccine Engineering 148

Drug Discovery World

FEBRUARY 20, 2024

Licensing for human use Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination. Imagine a future where vaccines are not only more affordable but also provide consistent protection in fewer doses, without causing discomfort or requiring refrigeration.”

Vaccine 130

Vaccine Immune Response Licensing Licensing 130

Drug Discovery World

NOVEMBER 30, 2022

million to support further development of the re-engineered technology for use in the global response to future disease outbreaks. . Importantly, this re-engineered technology does not pose any issue with diagnostic interference as was encountered in 2020.” . Clamp technology .

Vaccine 130

Vaccine Immune Response Virus Engineering 130

Drug Discovery World

JANUARY 11, 2023

AbbVie and Immunome have agreed a worldwide collaboration with the aim of discovering up to 10 novel antibody-target pairs arising from three specified tumour types using Immunome’s Discovery Engine. . We look forward to utilising their Discovery Engine to enhance our existing oncology pipeline.” .

Immune Response 130

Immune Response Engineering Therapies Research 130

Drug Discovery World

APRIL 11, 2024

We have noted that cancer patients can develop powerful anti-tumour immune responses that can result in complete cure of the disease and we call these patients ‘elite responders’. By understanding what triggers the adaptive immune response in “elite responders” we have identified new targets and therapeutic antibodies.

Research 148

Research Immune Response Disease Laboratories 148

Science Daily: Pharmacology News

OCTOBER 18, 2023

Immunotherapies, which mobilize the body's immune defenses against a cancer, have not been effective for GBM, in part because the tumor's surrounding environment is largely impenetrable to assaults from the body's immune system.

Therapies 77

Therapies Immune Response Research Virus 77

Drug Discovery World

AUGUST 2, 2022

Secondary endpoints will evaluate treatment efficacy, including progression-free and overall survival as well as any immune response to NeuroNova. . NeuroNova is an allogeneic “off-the-shelf” therapy comprised of an immortalised Neural Stem Cell (NSC) line loaded with an engineered oncolytic adenovirus.

Trials 130

Trials FDA Immune Response Clinical Trials 130

Drug Target Review

JUNE 27, 2023

This ebook delves into the intricate world of cancer therapies, immune system breakthroughs, therapeutic genetic engineering, and groundbreaking advancements in gene editing, featuring insightful interviews with renowned experts in the field.

Therapies 105

Therapies Immune Response Engineering Drugs 105

Drug Discovery World

NOVEMBER 16, 2022

They regulate tissue repair and regeneration, organ development, and immune response to disease but remain understudied by biopharma due to low abundance, higher structural complexity, and the massive search space to map secreted proteins to disease-reversing effects in specific target cells across human organs.

Disease 130

Disease Engineering Immune Response FDA Approval 130

Broad Institute

JULY 11, 2024

Treatment with mIDH1 blockers unearths these remnants, triggering an immune response against the tumor cells. This immune response relies on the expression of a gene called cGAS , which produces part of a protein that detects retroviruses.

Treatment 72

Treatment Immune Response Virus Drugs 72

Drug Target Review

AUGUST 11, 2023

1 The study reveals a novel bioinformatic approach and tool that holds the potential to empower researchers in designing vaccines capable of inducing a stronger immune response. By selecting specific segments of proteins that elicit robust immune reactions, these vaccines could offer enhanced protection against diseases.

Vaccine 98

Vaccine Immune Response Bioinformatics Virus 98

Drug Discovery World

JANUARY 22, 2024

The MIS is developing novel vaccine concepts for broad and potent protective immune responses against influenza virus for patients, as well as to provide a mechanistic principle for designing vaccines for other hypervariable pathogens such as coronaviruses and HIV-1 2.

Immune Response 148

Immune Response Vaccine Engineering Virus 148

Drug Discovery World

SEPTEMBER 9, 2022

A new genetically engineered herpes virus has delivered a one-two punch against advanced cancers in initial findings from a Phase I trial. The genetically engineered RP2 virus, which is injected directly into the tumours, is designed to have a dual action against tumours. Of these, six remained progression-free at 14 months.

Virus 130

Virus Research Immune Response Engineering 130

Drug Discovery World

FEBRUARY 19, 2024

The paper evaluated a transplant of Sana Biotechnology’s engineered allogeneic, HIP-modified pancreatic islet cells into a fully immunocompetent, diabetic NHP. C-peptide levels reached normal levels and there was no indication that the allogeneic HIP p-islet graft induced any immune recognition or any type of immune response at any time.

Therapies 130

Therapies Immune Response Engineering Trials 130

Drug Discovery World

FEBRUARY 6, 2023

This is part of why patients in trials and the clinic can experience severe toxicity and adverse events, reject their therapy with an immune response, or completely fail to respond to treatment. This has consequences for safety and efficacy. Starting from antibodies found in humans is a better strategy.

Immune Response 130

Immune Response Clinical Trials Drug Development Production 130

Drug Target Review

DECEMBER 28, 2023

These neoantigens are identified by T cells of the immune system as foreign proteins and thus trigger an immune response. Neoantigens are recognised as non-self and trigger an immune response.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

Drug Target Review

OCTOBER 26, 2023

Genome engineering and gene therapies that manipulate DNA sequences in cells have driven a biotechnological revolution over the past decade. 9 In addition, host immune responses further add to the complexity of developing cell-specific AAV capsids for clinical applications. His mentorship produced numerous publications.

Engineering 105

Engineering Virus Therapies Immune Response 105

PLOS: DNA Science

OCTOBER 12, 2023

Can they deliver healing genes without triggering an overactive immune response? The details are disturbingly reminiscent of the famous case of Jesse Gelsinger , who died from a ferocious immune response to experimental gene therapy in September 1999. An immune response is two-tiered.

Therapies 69

Therapies Immune Response DNA Virus 69

Drug Discovery World

JULY 5, 2023

Decades of research on the cellular and molecular mechanisms of how the immune system detects and kills cancerous or pre-cancerous cells, known as immune surveillance, and the factors which modulate that response, have led to understanding how we can enable a patient’s own immune system to fight cancer more efficiently in different ways.

Research 246

Research Immune Response Pharmaceutical Companies Treatment 246

Drug Discovery World

OCTOBER 21, 2022

Ibrahim Ozbolat, Professor of Engineering Science and Mechanics, Biomedical Engineering and Neurosurgery, Penn State, explained how their work will impact cancer research: “We’ve developed a tool that serves as a clinical test platform to safety and accurately evaluate experimental therapies.

Therapies 130

Therapies Small Molecule Immune Response Engineering 130

The Pharma Data

DECEMBER 17, 2020

Merck will select cancer targets and harness Janux’s proprietary Tumor Activated T Cell Engager (TRACTr) technology to engineer novel, T cell engager drug candidates. Janux technology can be applied to immunotherapies that target all three stages of an anti-tumor immune response.

Immune Response 52

Immune Response Pharmacokinetics Engineering Licensing 52

Drug Discovery World

NOVEMBER 10, 2023

Dense aggregates of immune cells, including CD8 positive granzyme B positive cytotoxic T cells, dendritic cells, and B cells, were observed in PDAC tissue after CAN-2409 treatment, confirming activation of a robust antitumoral immune response.

Pharmacokinetics 130

Pharmacokinetics Clinical Trials Immune Response Treatment 130

Drug Target Review

SEPTEMBER 11, 2023

This sugar-coated mucin binding to checkpoint receptors signals that the cancer cell poses no threat, consequently blocking the immune response. Tender elaborated that these results in immune cells ignoring the cancer rather than eliminating it, as they normally would.

Immune Response 116

Immune Response Research Engineering Virus 116

Drug Discovery World

FEBRUARY 28, 2024

Dr Nigel Blackburn, Director of Cancer Research UK’s Centre for Drug Development, says: “What’s interesting about IgE is its involvement in our body’s defence against parasites and the particularly powerful immune response it elicits. expressing cancers.

Drug Development 163

Drug Development Research Clinical Trials Drugs 163

Drug Target Review

OCTOBER 16, 2023

2D cell models are often engineered to over-express the target of interest and so lack its temporal behaviour in its native or disease state. This is particularly pertinent in immune-based cell therapies like CAR-T, where animals do not mimic the human immune response.

Disease 122

Disease Immune Response Cell Biology Engineering 122

Drug Target Review

APRIL 26, 2023

We are hopeful that it can be used to treat or repair a range of genetic diseases, including cystic fibrosis,” said Daniel Anderson, a Professor in MIT’s Department of Chemical Engineering and a member of MIT’s Koch Institute for Integrative Cancer Research and Institute for Medical Engineering and Science (IMES).

RNA 98

RNA Medical Schools Engineering DNA 98

The Pharma Data

APRIL 22, 2023

However, many of those therapies cause severe side effects in different parts of the body, including the immune system itself, and thus carry significant health risks. Now, a research team at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard John A.

Therapies 40

Therapies Immune Response Small Molecule Engineering 40

Broad Institute

AUGUST 7, 2023

MIT biology PhD student Bingxu Liu and Rebecca Carlson PhD ’23, a recent graduate of the Medical Engineering and Medical Physics program through the Harvard-MIT Division of Health Sciences and Technology, are the lead authors of the paper, which appears in Science.

Regulations 91

Regulations Engineering Clinical Trials DNA 91

The Pharma Data

DECEMBER 16, 2020

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. About Novavax. Novavax, Inc.?(Nasdaq: Novavax Forward Looking Statements.

Government 52

Government Vaccine Immune Response Clinical Trials 52

The Pharma Data

DECEMBER 13, 2020

SYNB1891 is an investigational drug for the intra-tumoral treatment of solid tumors and lymphoma, composed of an engineered Synthetic Biotic designed to activate the STING pathway in the tumor microenvironment in order to upregulate the patient’s immune response. Synlogic’s President and Chief Executive Officer.

Immune Response 40

Immune Response Treatment Engineering Clinical Trials 40

Advarra

JANUARY 11, 2024

After injection of such a vaccine, the mRNA instructs cells to produce proteins designed to stimulate an immune response against these same protein targets when they show up in viruses or in tumor cells. Adoptive T Cell Therapies Adoptive T cell therapy is another form of cancer treatment leveraging the patient’s immune system.

Vaccine 52

Vaccine Therapies Clinical Trials Small Molecule 52

The Pharma Data

NOVEMBER 22, 2020

The Agreement extends an existing relationship between the companies and gives Pandion the option to use standard phage display or mammalian display as the engines for the discovery of next generation antibodies.

Immune Response 52

Immune Response Engineering Clinical Research Disease 52

The Pharma Data

JUNE 1, 2022

Blocking an immune response-related enzyme holds promise in preventing or treating severe COVID-19 symptoms by reducing inflammation, tissue injury and blood clots in the lungs, new research in mice suggests. Previous research has shown that caspase 11 in mice has many of the same immune-response functions as caspase 4 in humans.

Immune Response 52

Immune Response Virus Engineering Disease 52

Broad Institute

DECEMBER 6, 2023

Using single-cell RNA sequencing to analyze gene expression in individual cells, the researchers have found how 86 major cytokines affect 17 immune cell types in mice. NH: This is the first single-cell resolution dictionary of each major immune cell type responding to each major cytokine in vivo at an unprecedented scale.

Immune Response 138

Immune Response RNA Medical Schools Disease 138

Drug Target Review

FEBRUARY 7, 2024

We had built a machine learning classifier that has been trained to identify amino acid sequences that have the potential to mimic ‘host defense peptides’ from the human innate immune system. Such peptides play a critical role in the machinery for amplifying innate immune responses.

RNA 69

RNA Virus Immune Response Engineering 69

NIH Director's Blog: Drug Development

FEBRUARY 1, 2022

The decoy is a specially engineered protein particle that mimics the 3D structure of the ACE2 receptor , a protein on the surface of our cells that the virus’s spike proteins bind to as the first step in causing an infection. They engineered a new soluble version of ACE2 that structurally might work better as a decoy than the original one.

Virus 52

Virus Engineering Clinical Trials Immune Response 52